Targeting p53 for enhanced radio- and chemo-sensitivity.
about
Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapyTargeting apoptosis pathways in cancer with alantolactone and isoalantolactoneResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage responseMore targets, more pathways and more clues for mutant p53.Targeting p53 for Novel Anticancer Therapy.p53 suppresses structural chromosome instability after mitotic arrest in human cells.p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing.The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.p53 Family and Cellular Stress Responses in Cancer.p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cellsAcute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.A mammalian functional-genetic approach to characterizing cancer therapeutics.IER3 is a crucial mediator of TAp73β-induced apoptosis in cervical cancer and confers etoposide sensitivity.The p53-reactivating small molecule RITA induces senescence in head and neck cancer cellsGlycogen synthase kinase 3β inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway.HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.MG132 inhibition of proteasome blocks apoptosis induced by severe DNA damage.Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.HEY1 Leu94Met gene polymorphism dramatically modifies its biological functionsTumour suppressor genes in chemotherapeutic drug response.Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression.The transcription factor CREBZF is a novel positive regulator of p53.Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cellsThe Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs.Therapeutic targeting of the p53 pathway in cancer stem cells.Hedgehog signaling in prostate cancer and its therapeutic implicationRole of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma.Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.HEY1 functions are regulated by its phosphorylation at Ser-68.Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo.Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China.MicroRNAs in the ionizing radiation response and in radiotherapy.Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors.MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells.Simultaneous analysis of p53 protein expression and cell proliferation in irradiated human lymphocytes by flow cytometry.
P2860
Q26768521-85DDE840-D64F-414D-A80B-4F13B99CA193Q26850232-0E9853AF-3089-4F16-A439-11298DB5DA13Q27006998-83614B0A-B924-4B4C-BBC0-E02684DC32BCQ28594239-29D98C94-8D82-4684-BC3C-C80D1FBA7494Q30542607-170DFB14-BCF9-4CD7-BCB5-F7E4F7C0A52BQ33655329-8E5D208E-EEEF-42DF-8F85-F4611097E725Q33766312-DE12A44B-CFE3-4572-806F-40A40B419FE9Q33939746-5B68218D-45CB-44E3-9DF5-CEFE9AA6BD56Q34171407-B502A29E-C42E-46A3-A3CD-4D638BAD0565Q34294432-BE107B97-FEA1-4791-922E-96D667D78776Q34377287-5830EBC9-57FE-442E-BACF-3EF819A0371BQ34428159-3A7892C8-6640-4185-9180-04CC97AD34DBQ34634251-AEA84DA4-3FD5-4F43-AC6A-59EF1B551109Q34760557-7E2F6BE5-DED6-41B6-B895-D08314B2B3B9Q35065736-03AAA36D-E9A7-41B7-8F79-02421B0185D5Q35224002-E8687AA6-480E-477F-9D7F-29836034E73AQ35354504-6762A269-DEB4-457B-BB53-E99B96EEAB00Q35475401-14897972-590F-4DED-80A9-BF296CD32CD4Q35568870-6A1A6E2D-55E5-4525-A509-2F04F278F38AQ35695025-A770B3B6-16DD-42A3-AA76-4B37FCBEA638Q35951042-1981096C-6E15-4921-BE10-C004DD61398EQ36054564-A652283B-5E93-4DDF-9D13-47312CA1109FQ36083098-9AC435F4-9109-4CCE-8330-FBDB90EA83B0Q36086628-8B2CB801-1185-4EE4-AA47-485D8780FD68Q36392179-1313220B-7DC7-4F3D-A00B-97776A2EA263Q36581674-9ECDCAED-7B5D-484B-B2EE-3FCBAF276BEBQ36591517-318EAA94-EB33-4DC9-8B06-E4816646D344Q36832574-1987C8A0-FB45-4139-BA28-0B8064A51312Q36833275-DFA763DC-2F3F-403D-9689-E00498B17E63Q37091887-6017B418-E45A-442A-ABBA-18453CA2A756Q37252274-60825DD8-6D5B-4D08-ADF6-0E56B27F954FQ37484082-A4FD5AD6-3828-4846-BF19-D6DD59075AEFQ37571729-87E04950-C087-4F28-BAB1-F398D6FCAA41Q37626853-4D82B185-C73A-4E59-BA3C-FD0A68270E5EQ37703533-54298460-930E-4EA1-932A-1454B3CFB3C7Q37724094-D7880737-9F28-455C-8C02-E2D48C04FB6EQ38085906-09D65D54-8D80-4676-AD88-2C06530EB1CDQ38286386-61BD680A-2592-49E7-910F-E1ADB4F46981Q38301131-55EEB341-9994-43EB-978A-C39D93836CC0Q38370284-8433DB68-7B8A-4769-9FED-E95C645F7E67
P2860
Targeting p53 for enhanced radio- and chemo-sensitivity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting p53 for enhanced radio- and chemo-sensitivity.
@en
Targeting p53 for enhanced radio- and chemo-sensitivity.
@nl
type
label
Targeting p53 for enhanced radio- and chemo-sensitivity.
@en
Targeting p53 for enhanced radio- and chemo-sensitivity.
@nl
prefLabel
Targeting p53 for enhanced radio- and chemo-sensitivity.
@en
Targeting p53 for enhanced radio- and chemo-sensitivity.
@nl
P2860
P1433
P1476
Targeting p53 for enhanced radio- and chemo-sensitivity
@en
P2093
P2860
P2888
P304
P356
10.1007/S10495-009-0330-1
P577
2009-04-01T00:00:00Z